Elekta acquires Resonant Medical Inc., adding new solutions for image guided
radiation therapy for treating cancer.
Groundbreaking non-invasive, non-ionizing image guidance technology enables
exquisite visualization of soft tissue targets, provides promising platform for next
generation motion management.
Press Release
Stockholm, Sweden, May 31, 2010
Elekta today announced the acquisition of Resonant Medical Inc., Montreal Canada.
Through this acquisition, Elekta adds exciting new solutions for image guidance as well
as highly skilled R&D resources in the field of oncology imaging and motion
management.
Resonant Medical Inc. (‘RMI’) develops systems for image guided radiation therapy of
soft tissues using latest generation, 3-D ultrasound technology. Subject to customary
closing conditions, Elekta will pay CAD 30 M in cash for the outstanding shares of RMI.
RMI’s integrated software solutions have been developed in cooperation with leading
academic institutions to improve treatment accuracy for cancer in the prostate, breast,
liver, cervix, uterus, bladder as well as head and neck. RMI’s equipment is in daily
clinical use in the US, Canada, Italy, The Netherlands and Ireland and its research
collaborators are considered among the world leaders in their field.
Elekta’s President and CEO Tomas Puusepp said “This is really exciting, as it further
enhances Elekta’s state-of-the-art solutions in IGRT, by adding RMI’s leadership in soft
tissue visualization and tracking, especially focused on innovative solutions for breast
and prostate cancer. In addition, given Elekta’s dedication to open architecture, the
technology will be made available to customers with other vendors’ equipment, making
it possible to improve IGRT processes everywhere.”
RMI’s current products will continue to operate with linear accelerators from all
manufacturers and provide outstanding image guidance for soft tissue targets,
especially in the breast and pelvic area, without additional x-ray dose or using invasive
implanted markers. They can add high quality IGRT to the thousands of linacs in use
today that do not have integrated imaging systems, while the soft tissue detail is also
highly complementary to linacs already equipped with cone beam CT or MV (portal)
imaging.
In addition, RMI will provide useful additions to Elekta’s MOSAIQ® treatment planning
solutions by displaying soft tissue structures, not easily seen on X-ray computed
tomography but in exact spatial correlation with these CT images, and offering a suite
of automatic segmentation and contouring tools.
“Elekta has gained an experienced development team with mature, easy-to-use, stable
clinical products. And the established sales and marketing infrastructure of Elekta is
the perfect foundation to further introduce this valuable technology to the radiation
oncology market. Beyond just today however, the really exciting things are yet ahead
as we start to integrate RMI:s solutions with MOSAIQ and in the future with our stateof-
the art linear accelerators”, says Elekta’s President and CEO Tomas Puusepp.
RMI was founded in 2000 based on research from McGill University, Montreal. The
CEO of the company, Tony Falco, Ph.D. is one of the founders and has over 15 years
experience in advanced imaging technology; clinical, product development, supply,
and IP creation. The company has 35 employees, of whom most are based in
Montreal, Canada.
Tony Falco, CEO of RMI, says: “These are exciting times. RMI provides solutions
compatible with all vendors’ simulators and linear accelerators and together with
Elekta’s world-wide customer network it provides us for the first time with the ability to
improve clinical standards on a global basis. In addition, being fully integrated with a
leading clinical solutions provider like Elekta makes it possible for us to deliver truly
unique integrated clinical solutions in the future, all of which is important in improving
patient care.”
Elekta expects to consolidate RMI into its accounts as from June 1st, 2010. The
revenue for 2010/11 is expected to be around CAD 10 M. The transaction is
forecasted to have a minor dilutive effect on reported earnings per share during fiscal
year 10/11 and be mildly accretive the following fiscal year.
###
For further information, please contact:
Todd Powell, Executive Vice President, Elekta Software, Elekta AB
Tel: +1 650 823 3085, email: todd.powell@elekta.com
Time zone: PDT: Pacific Daylight
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, Mobile tel: +46 70 778 60 10 email: stina.thorman@elekta.com
Time zone: CET: Central European
About Elekta
Elekta is a human-care company pioneering significant innovations and clinical solutions
for treating cancer and brain disorders. The company develops sophisticated, state-of-theart
tools and treatment-planning systems for radiation therapy and radiosurgery, as well as
workflow-enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resourceefficient
solutions that offer confidence to both health-care providers and patients, Elekta
aims to improve, prolong and even save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals
globally, and every day more than 100,000 patients receive diagnosis, treatment or followup
with the help of a solution from the Elekta Group. Elekta employs around 2,500
employees globally. The corporate headquarter is located in Stockholm, Sweden, and the
company is listed on the Nordic Exchange under the ticker EKTAb. For more information
about Elekta, visit www.elekta.com.
